GT Biopharma (GTBP) announced the submission of an investigational new drug, IND, application to the U.S. Food and Drug Administration, FDA, in December 2025 for GTB-5550 TriKE, a B7-H3-targeted natural killer cell engager for the treatment of B7-H3 expressing solid tumor cancers.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTBP: